arrow
R

Ruth Perets

technion israel institute of technology
H指数:23
被引数:4,125

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

Nivolumab联合relatlimab和nivolumab联合ipilimumab治疗晚期肾细胞癌患者: 开放标签,随机,II期分次RCC试验的结果

2024-12-010
PRE
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

simlukafusp alfa (FAP-IL2v) 联合阿特珠单抗治疗复发和/或转移性宫颈鳞状细胞癌患者的抗肿瘤活性和安全性的2期研究

2024-11-011
PRE
Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer
2024-09-150
PRE
Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)

AZD5335的一期人体研究结果,该药物是一种叶酸受体α(FRa)靶向抗体药物偶联物,用于治疗对铂类耐药的复发性卵巢癌(PRROC)患者(pts)。

2024-09-010
PRE
Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

I期首次人体剂量递增研究的结果,该研究评估了第一类抗ILT2抗体SAR444881单药及联合pembrolizumab或cetuximab在晚期实体瘤患者中的疗效。

2024-09-010
PRE
Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors
2024-04-050
PRE
Intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L/IL-23/IL-36γ in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment (TME) of patients with advanced solid tumors
2024-03-221
PRE
PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: PART 1 RESULTS
2022-12-081
OA

研究方向

暂未获取到该数据
暂无数据